Table 1.
Baseline characteristics of HCM patients with and without HighT2
| Total (n = 109) | HighT2 present (n = 29) | HighT2 absent (n = 80) | p value | |
|---|---|---|---|---|
| Age (years) | 54 ± 15 | 52 ± 14 | 55 ± 15 | .29 |
| Men | 61 (56) | 20 (69) | 41 (51) | .10 |
| Age at diagnosis (years) | 47 ± 16 | 44 ± 15 | 49 ± 16 | .20 |
| Pathogenic mutation present | 59 (58) | 15 (58) | 44 (58) | .99 |
| Atrial fibrillation | 18 (17) | 5 (17) | 13 (16) | 1.0 |
| Hypertension | 40 (37) | 9 (31) | 31 (39) | .46 |
| Symptoms | ||||
| Chest pain | 21 (19) | 3 (10) | 18 (23) | .16 |
| Dyspnea (NYHA class ≥ II) | 49 (45) | 17 (59) | 32 (40) | .08 |
| Therapy | ||||
| Beta-blocker | 51 (47) | 13 (45) | 38 (48) | .81 |
| Calciumantagonist | 16 (15) | 3 (10) | 13 (16) | .55 |
| Troponin T concentration (ng/L) | 8 (3–14) | 15 (8–25) | 7 (3–12) | < .001 |
| CMR Imaging | ||||
| LVMI (g/m2) | 62 (52–87) | 85 (63–116) | 59 (51–74) | < .001 |
| LV ejection fraction (%) | 59 ± 7 | 55 ± 7 | 61 ± 6 | < .001 |
| LGE present (n) | 68 (65) | 26 (93) | 42 (55) | < .001 |
| LGE extent (% of LV mass) | 3 (0–10) | 10 (4–19) | 1 (0–7) | < .001 |
Data are presented as means ± standard deviations, medians (interquartile ranges) or numbers (percentages)
HighT2 high signal intensity on T2-weighted imaging, NYHA New York Heart association, CMR cardiovascular magnetic resonance, LV left ventricle, LVMI LV mass indexed to body surface area, LGE late gadolinium enhancement